GlassScriptPhysician profile
Philip K DO
NPI 1417006305
$3,320.14
in general payments reported to CMS, 2019-2025
14 companies · $463 in 2025
The $463 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2021: $375 · 2022: $725 · 2023: $522 · 2024: $766 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,067.93 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Vision Care, INC. | $523.78 | 2022-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $243.60 | 2019-2021 | |
| Allergan, INC. | $233.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $146.18 | 2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Abbvie INC. | $125.00 | 2025 | |
| Oyster Point Pharma, INC. | $125.00 | 2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| Shire North American Group INC | $124.50 | 2019 | |
| Sight Sciences, INC. | $123.64 | 2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $121.95 | 2023 | Cequa |
| Visionix USA, INC | $118.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $116.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.